MyFinsight
Home
Blog
About
Contact
Download
Download image
US
$1,104,973K
Europe
$874,331K
Rest Of World
$544,469K
Latin America
$435,478K
Products Excluding
ALDURAZYME-Sales Channel...
$2,959,251K
ALDURAZYME-Sales Channel Through
Intermediary
$208,508K
Product
$3,167,759K
(12.75%↑ Y/Y)
Royalty And Other
$53,494K
(20.29%↑ Y/Y)
Total revenues
$3,221,253K
(12.87%↑ Y/Y)
Income from operations
$409,478K
(-15.43%↓ Y/Y)
Interest income
$74,904K
(0.03%↑ Y/Y)
Total operating
expenses
$2,811,775K
(18.66%↑ Y/Y)
Other income
(expense), net
$8,997K
(292.74%↑ Y/Y)
Income before income
taxes
$482,480K
(-10.94%↓ Y/Y)
Interest expense
$10,899K
(-13.95%↓ Y/Y)
Selling, general and
administrative
$1,153,017K
(14.27%↑ Y/Y)
Research and development
$921,930K
(23.39%↑ Y/Y)
Cost of sales
$717,442K
(23.65%↑ Y/Y)
Intangible asset
amortization
$19,386K
(-55.18%↓ Y/Y)
Net income
$348,901K
(-18.26%↓ Y/Y)
Provision for income taxes
$133,579K
(16.25%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
biomarin-logo-svg
BIOMARIN PHARMACEUTICAL INC (BMRN)
biomarin-logo-svg
BIOMARIN PHARMACEUTICAL INC (BMRN)